olivLaw · US equity research
BrainsWay Ltd. BWAY
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
BrainsWay is a global producer of deep transcranial magnetic stimulation (Deep TMS) systems for mental health disorders, with three FDA-cleared indications. The company reported higher revenue in 2025 of 52.2 million USD, and 1,781 systems were installed at year end.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, BrainsWay Ltd. (BWAY) stock was 11.21 USD (+0.54% on the day), with market capitalisation 439.0 m USD, P/E 224.2 on diluted EPS of 0.05 USD over the last 12 months, beta 1.26, 52-week range 7.25–17.17 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 40.2
- weak (30–45)
- Bollinger (20, 2)
- 10.95 – 12.15
- in the lower half of the band · %B 0.22 · band width 10.4%
- SMA 50 / 200
- 12.76 / 13.92
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.43 / -0.47
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −8.3% | −2.0% | −6.3 pp | — |
| 3 months | −25.3% | −2.2% | −23.2 pp | — |
| 6 months | −31.7% | +4.3% | −36.0 pp | — |
| Year to date | +17.9% | +10.6% | +7.3 pp | — |
| 1 year | +34.2% | +10.5% | +23.7 pp | −5.6% |
| 3 years | +444.2% | +73.7% | +370.5 pp | +6.7% |
| 5 years | +163.8% | +61.7% | +102.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 1-quarter history (min 94.3, median 94.3, max 94.3; quarters with earnings only).
Fiscal years
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.1 m | 16.4 m | 23.1 m | 22.1 m | 29.7 m | 27.2 m | 31.8 m | 41.0 m |
| Revenue YoY | unavailable | +47.1% | +40.9% | −4.5% | +34.5% | −8.4% | +17.0% | +29.0% |
| Net income | -7.1 m | -6.5 m | -10.3 m | -5.4 m | -6.5 m | -13.3 m | -4.2 m | 2.9 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | -0.21 | -0.40 | -0.13 | 0.05 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -63.3% | -39.5% | -44.7% | -24.4% | -21.8% | -49.1% | -13.2% | 7.1% |
| Free cash flow | -4.5 m | -5.7 m | -10.6 m | -3.9 m | -1.4 m | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2024 · 31 Dec 2024
- Cash
- 69.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 62.3 m USD
- Total assets
- 94.3 m USD
- Debt / equity
- unavailable
- Current ratio
- 5.19x
- ROE
- 5.6%
- ROA
- 3.7%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 23.1 m | 22.1 m | 29.7 m | 27.2 m | 31.8 m | 41.0 m | SEC (XBRL)· 22 Apr 2025verified |
| Cost of revenue | 5.1 m | 5.1 m | 6.6 m | 7.1 m | 8.3 m | 10.4 m | SEC (XBRL)· 22 Apr 2025verified |
| Gross profit | 18.0 m | 17.0 m | 23.1 m | 20.0 m | 23.5 m | 30.6 m | SEC (XBRL)· 22 Apr 2025verified |
| Research & development | 7.9 m | 5.8 m | 6.4 m | 7.7 m | 6.7 m | 7.2 m | SEC (XBRL)· 22 Apr 2025verified |
| Operating income | -8.5 m | -4.8 m | -5.0 m | -12.7 m | -5.0 m | 1.4 m | SEC (XBRL)· 22 Apr 2025verified |
| Interest expense | 1.4 m | 319.0 k | -1.7 m | 1.5 m | 1.2 m | 1.5 m | SEC (XBRL)· 22 Apr 2025verified |
| Pre-tax income | -9.9 m | -5.1 m | -6.4 m | -13.0 m | -3.9 m | 3.5 m | SEC (XBRL)· 22 Apr 2025verified |
| Income tax | 422.0 k | 237.0 k | 43.0 k | 315.0 k | 251.0 k | 538.0 k | SEC (XBRL)· 22 Apr 2025verified |
| Net income | -10.3 m | -5.4 m | -6.5 m | -13.3 m | -4.2 m | 2.9 m | SEC (XBRL)· 22 Apr 2025verified |
| Diluted EPS | — | — | -0.21 | -0.40 | -0.13 | 0.05 | SEC (XBRL)· 22 Apr 2025verified |
Balance sheet · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 21.7 m | 17.0 m | 16.9 m | 47.6 m | 10.5 m | 69.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Inventories | — | — | — | 3.8 m | 3.7 m | 4.4 m | SEC (XBRL)· 22 Apr 2025verified |
| Current assets | 28.8 m | 24.3 m | 65.4 m | 58.1 m | 55.5 m | 79.7 m | SEC (XBRL)· 22 Apr 2025verified |
| Property, plant & equipment, net | 4.2 m | 4.4 m | — | — | — | — | SEC (XBRL)· 19 Apr 2021verified |
| Total assets | 38.7 m | 34.0 m | 75.7 m | 64.5 m | 63.0 m | 94.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Accounts payable | 3.4 m | 3.8 m | 4.8 m | 4.5 m | 5.3 m | 5.9 m | SEC (XBRL)· 22 Apr 2025verified |
| Current liabilities | 6.7 m | 6.8 m | 9.1 m | 8.1 m | 9.8 m | 15.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Equity | 24.2 m | 19.6 m | 57.3 m | 45.4 m | 41.6 m | 62.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Shares outstanding at year end | 22.2 m | 22.3 m | 32.9 m | 33.1 m | 33.2 m | 37.6 m | SEC (XBRL)· 22 Apr 2025verified |
Cash flow · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.2 m | -1.4 m | 884.0 k | -9.8 m | 1.3 m | 10.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Capex | 3.3 m | 2.5 m | 2.2 m | — | — | — | SEC (XBRL)· 12 Apr 2022verified |
| Free cash flow | -10.6 m ≈ | -3.9 m ≈ | -1.4 m ≈ | — | — | — | SEC (XBRL)· 12 Apr 2022derived |
| Investing cash flow | -2.4 m | -2.5 m | -42.2 m | 42.2 m | -37.4 m | 30.3 m | SEC (XBRL)· 22 Apr 2025verified |
| Financing cash flow | 22.5 m | -1.0 m | 41.5 m | -1.5 m | -1.0 m | 18.3 m | SEC (XBRL)· 22 Apr 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 439.0 m USD
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
35% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.83 – 1.64 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E0.83 – 1.64 (Mid 1.22)12 companies used · median multiple 24.3x · quartiles 16.6x – 32.8xBSX, DXCM, EMBC, GCTK, GMED, LMAT, MMM, MMSI, RMD, SOLV, SYK, WST
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 7.1% | 62 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 11.4% | 95 (on a fixed band) | 24% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 0.9x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 5.2x | 100 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | 224.2x | 0 (vs peers) | 29% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial95/100 · 1/2 factors with a value
- Quality· partial62/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Brainsway Ltd. (BWAY). Latest full fiscal year: 2024; data up to 2024-12-31.
Figures computed from the financial statements: revenue 41.0 m USD in 2024; YoY growth 29.0%; net margin 7.1%; ROE 5.6%.
The estimated value range is 0.83–1.64 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 1.22 USD, the price of 11.21 USD leaves a potential of -89.1% (value / price − 1) and a margin of safety of -821.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 11.4%
- Current ratio: 5.2x
What contradicts it
- Interest coverage: 0.9x
- P/E (TTM): 224.2x
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 118.2 bn | 33.1 | 16.0% | 13.8% | +11.2% | −16% / +5% |
| MMM3m Company | 91.5 bn | 26.4 | 80.8% | 14.0% | +1.5% | +3% / +114% |
| BSXBoston Scientific Corporation | 63.1 bn | 18.4 | 14.3% | 16.6% | +19.9% | −57% / −22% |
| BDXBecton, Dickinson And Company | 54.0 bn | 59.8 | 3.8% | 4.0% | +8.2% | +30% / +7% |
| RMDResMed Inc. | 31.9 bn | 20.7 | 26.4% | 27.8% | +9.9% | −11% / +44% |
| DXCMDexcom, Inc. | 30.9 bn | 32.7 | 37.7% | 19.4% | +15.6% | +31% / −28% |
| WSTWest Pharmaceutical Services, Inc. | 28.4 bn | 45.7 | 21.2% | 18.8% | +6.3% | +47% / +16% |
| SOLVSolventum Corporation | 15.2 bn | 10.9 | 34.0% | 17.3% | +0.9% | +5% / unavailable |
| PENPenumbra, Inc | 12.7 bn | 81.2 | 10.7% | 10.1% | +17.5% | +10% / +45% |
| GMEDGlobus Medical, Inc. | 11.7 bn | 22.3 | 11.8% | 17.0% | +16.7% | −4% / +94% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| HAEHaemonetics Corporation | 5.8 bn | 62.3 | 11.2% | 7.1% | −2.0% | +57% / +58% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 34.0 | 9.8% | 9.9% | +11.8% | +5% / +27% |
| HTFLHeartflow, Inc. | 4.9 bn | — | — | -55.8% | +39.9% | +75% / unavailable |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| LMATLemaitre Vascular, Inc. | 2.0 bn | 30.9 | 16.8% | 25.0% | +13.5% | +6% / +67% |
| TNDMTandem Diabetes Care, Inc. | 1.3 bn | — | -48.0% | -6.1% | +7.9% | −9% / −6% |
| IARTIntegra Lifesciences Holdings Corp | 1.2 bn | 88.3 | 1.2% | 0.8% | +1.5% | +13% / −62% |
| BBNXBeta Bionics, Inc. | 921.5 m | — | -23.9% | -65.3% | +53.9% | −46% / unavailable |
| SGHTSight Sciences, Inc. | 533.3 m | — | -48.4% | -35.7% | −3.1% | +16% / +184% |
| SSIISs Innovations International, Inc. | 454.9 m | — | -26.1% | -23.7% | +105.7% | −66% / unavailable |
| CARLCarlsmed, Inc. | 439.3 m | — | -6,196.9% | -57.4% | +85.9% | −1% / unavailable |
| BWAYBrainsway Ltd. | 439.0 m | 224.2 | 5.6% | 7.1% | +29.0% | +34% / +444% |
| EMBCEmbecta Corp. | 369.4 m | 4.4 | — | 8.6% | −3.8% | −49% / −64% |
| CLPTClearPoint Neuro, Inc. | 325.7 m | — | -167.5% | -79.4% | +17.8% | −30% / +76% |
1- and 3-year price returns: for BWAY from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 10.57 Total return -6% · Per year -6% | 18.63 Total return 66% · Per year 66% | 27.98 Total return 150% · Per year 150% |
| 3 years | 11.73 Total return 5% · Per year 2% | 23.13 Total return 106% · Per year 27% | 37.92 Total return 238% · Per year 50% |
| 5 years | 13.03 Total return 16% · Per year 3% | 28.71 Total return 156% · Per year 21% | 51.39 Total return 358% · Per year 36% |
- Exit P/E± 5.78
- Net margin± 4.05
- Annual revenue growth± 3.12
- Annual dilution± 0.34
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 20 Apr 2026; since then the company filed 6-K (02 Nov 2026), 6-K (26 Oct 2026), 6-K (21 Oct 2026), 6-K (19 Oct 2026), 6-K (13 Oct 2026), 6-K (29 Sept 2026).
In brief
BrainsWay is a global producer of deep transcranial magnetic stimulation (Deep TMS) systems for mental health disorders, with three FDA-cleared indications. The company reported higher revenue in 2025 of 52.2 million USD, and 1,781 systems were installed at year end 1.
SWOT
Strengths
- The company holds several FDA clearances for psychiatric disorders, more than other TMS makers, and a growing installed base, according to the report 1.
- The H-Coil platform and a broad body of clinical evidence support the positioning as a leader in noninvasive neurostimulation 1.
- The company reached operating profit in 2024 and 2025, which strengthens its internal funding capacity 1.
Weaknesses
- Geographic concentration on the U.S. market exposes the company to regulatory and reimbursement changes there 1.
- The company has past losses and an accumulated deficit, so continued profitability remains uncertain 1.
- Dependence on one major customer and on third-party suppliers for components creates operational vulnerabilities 1.
Opportunities
- Broader reimbursement and new indications, such as fatigue in multiple sclerosis or addictions, could open new markets 1.
- Shorter and accelerated protocols could increase access for patients and clinicians 1.
- International expansion through registrations and approvals in other countries could diversify revenue 1.
Risks
- Dependence on one customerhigh
Loss of business with the main customer could significantly affect revenue and operating results 1.
- Reimbursement and regulationhigh
Lack or loss of reimbursement coverage could make physicians reluctant to use the system 1.
- Competitionmedium
Competitors with lower costs could reduce market share and margins 1.
- MSO and Neurolief investmentsmedium
If due diligence fails to identify deficiencies, the company could be required to take write-downs or other accounting adjustments 1.
- Geopolitical risks in Israelmedium
Political and military conditions in Israel, where manufacturing is located, could affect operations 1.
Investment thesis
What would need to be true (bull case)
- If indication expansions and reimbursement strengthen, the revenue growth seen in 2025 could continue in the following years 1.
- Recent profitability and multiple FDA clearances could support continued investment in research and new indications 1.
- Shorter protocols could broaden patient access and increase the number of installed systems 1.
What would break the thesis
What to watch
- Development of revenue and installed systems compared with the 2025 levelQ1 2027
- Status of indication expansions and protocols approved by FDA2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 20 Apr 2026; since then the company filed 6-K (02 Nov 2026), 6-K (26 Oct 2026), 6-K (21 Oct 2026), 6-K (19 Oct 2026), 6-K (13 Oct 2026), 6-K (29 Sept 2026).
The business
BrainsWay Ltd. presents itself as a global leader in noninvasive neurostimulation for mental health disorders, based on its proprietary Deep TMS platform and patented H-Coils that stimulate deep and broad brain regions 1. The system is FDA-cleared for major depressive disorder (including anxious depression), obsessive-compulsive disorder and smoking addiction, and customers are mainly psychiatrists, clinics and hospitals 1. Revenue comes from sales or leases of systems, pay-per-use models and service fees 1.
Segments
Obsessive-compulsive disorder (OCD)
The first FDA-authorized noninvasive treatment for OCD, cleared in 2018 on the basis of a placebo-controlled study; the estimated U.S. addressable market is about 2.9 billion USD 1.
Smoking addiction
The first FDA clearance for any TMS device in the addiction space, received in August 2020; the company is collecting clinical data for a long-term commercial plan, with an estimated market of over 3.0 billion USD 1.
Market context
Trends
- Expansion of approved indicationstailwind
FDA expanded approvals for older and adolescent patients and for shorter protocols in 2024 and 2025, which could open new patient categories 1.
- Reduction of required failed medications for reimbursementtailwind
There is a growing trend to reduce the number of failed medication trials required for Deep TMS coverage, which could place treatment earlier in the patient pathway 1.
- Dependence on a single major customerheadwind
A significant portion of revenue has come from a single customer; losing this business could affect financial results 1.
- Investments in MSO and Neurolief transactionsmixed
The MSO and Neurolief transactions add diversification but also carry impairment and regulatory risks if due diligence fails to identify deficiencies 1.
Competitive position
The stated advantage lies in the H-Coil design, which stimulates deeper brain regions, and in the number of approved indications, where the company presents itself as the only TMS company with three such clearances 1.
- Companies that obtained FDA clearance for OCD
Companies that received OCD clearance partly relying on BrainsWay data, according to the report 1.
- Third-party component suppliers
Components used in manufacturing systems are bought from third parties, creating operational dependence 1.
- Other noninvasive neuromodulation providers
The company is compared with other mental health neuromodulation device makers, though the analyzed source does not name them 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- BrainsWay’s (BWAY) Growth Streak Just Got Harder To IgnoreYahoo Finance — News · 11 Sept 2026 · EN
The latest news item in our archive is from 11 Sept 2026; the newest SEC filing is from 02 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)21 Oct 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)13 Oct 2026
- Current report (foreign issuer)29 Sept 2026
- Current report (foreign issuer)08 Sept 2026
- Current report (foreign issuer)27 Aug 2026
- Current report (foreign issuer)12 Aug 2026
- Current report (foreign issuer)12 Aug 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / BrainsWay Ltd. · 20 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.